AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
CHINA BULLETIN: Europe Calls on China
In this week’s issue EU leaders come calling on China, Evergrande restructures and Airbus invests. On a scale of 1 to 10, we give the week a 5 for offshore-listed China stocks.
Past the Peak? Covid Drugs Frenzy Cools as Pandemic Eases
Simcere Pharmaceutical and Junshi Biosciences have gained marketing approvals for their Covid oral drugs, but the market reaction has been lukewarmKey Takeaways:The drugs Xiannuoxin and Mindewei have been conditionally approved…
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
The Hong Kong-traded company will become the latest from the cash-challenged pharma sector to make a second listing on the A-share market Key Takeaways: InnoCare Pharma’s A-share IPO will make…
Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins
Company licensed to sell BioNTech’s mRNA vaccine in China reported its revenue rose 28.8% last year, with the Comirnaty vaccine bringing in over $157 million Key takeaways: Fosun Pharma’s revenue…
Jiangsu Recbio Shoots to Become Hong Kong’s First HPV Vaccine Stock
The vaccine producer is making a second attempt to list in Hong Kong, as its core HPV vaccine undergoes Phase 3 clinical trials Key takeaways: Jiangsu Recbio has filed a…
Recent Articles
RELATED ARTICLES
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US - InSilico seeks IPO boost to get AI drugs over the line
- ProfoundBio discovers the joys of having a wealthy owner
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
